Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.


AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.


Comments are closed.

FDA expands approved use of Imbruvica for chronic lymphocytic leukemia
ANSM: Stresam® (étifoxine): Modification de l’AMM: libellé d’indication, données de pharmacovigilance et de pharmacodynamie
FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications
FDA Guidance for Industry: The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]
EMA: Meeting highlights from the CHMP 21-24 July 2014
European Medicines Agency recommends approval of two new treatment options for rare cancers
EMA: CMDh endorses suspension of methadone oral solutions containing high molecular weight povidone
FDA approves Zydelig for three types of blood cancers
FDA approves new extended-release oxycodone with abuse-deterrent properties
UK MHRA: European review concludes positive benefit risk of emergency contraceptives